Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

DOI: 10.1016/j.nmni.2020.100709
New Microbes and New Infections, 2020, 38, 100709.

#	Paper	IF	Citations
58	Lancet gate: a matter of fact or a matter of concern. *New Microbes and New Infections*, **2020**, 38, 100758	4.1	0
57	Preprints in Medicine: Useful or Harmful?. *Frontiers in Medicine*, **2020**, 7, 579100	4.9	3
56	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *International Journal of Antimicrobial Agents*, **2020**, 56, 106214	14.3	53
55	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. *Journal of General Internal Medicine*, **2020**, 35, 3308-3314	4	59
54	Chloroquine and COVID-19: A western medical and scientific drift?. *European Journal of Internal Medicine*, **2020**, 78, 4-5	3.9	3
53	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. *Travel Medicine and Infectious Disease*, **2020**, 36, 101791	8.4	162
52	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. *Clinical Microbiology and Infection*, **2021**, 27, 138-140	9.5	8
51	Familiar Dermatologic Drugs as Therapies for COVID-19. *Actas Dermo-sifiliográficas*, **2021**, 112, 118-126	0.5	1
50	Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. *International Journal of Antimicrobial Agents*, **2021**, 57, 106241	14.3	1
49	Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al. *Clinical Microbiology and Infection*, **2021**, 27, 132-133	9.5	0
48	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. *International Journal of Antimicrobial Agents*, **2021**, 57, 106222	14.3	13
47	Rational for meta-analysis and randomized treatment: the COVID-19 example. *Clinical Microbiology and Infection*, **2021**, 27, 6-8	9.5	4
46	Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. *Molecular Neurobiology*, **2021**, 58, 106-117	6.2	21
45	Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective. *3 Biotech*, **2021**, 11, 94	2.8	3
44	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. *Journal of Public Health Research*, **2021**, 10, 1945	2.2	2
43	Familiar dermatologic drugs as therapies for COVID-19. *Actas Dermo-sifiliográficas*, **2021**, 112, 118-126	0.5	0
42	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. *Microbial Drug Resistance*, **2021**, 27, 281-290	2.9	8

41	Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. *PLoS ONE*, **2021**, 16, e0248009	3.7	28
40	Publication by association: how the COVID-19 pandemic has shown relationships between authors and editorial board members in the field of infectious diseases. *BMJ Evidence-Based Medicine*, **2021**,	2.7	2
39	Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV).		2
38	Moments in autophagy and disease: Past and present. *Molecular Aspects of Medicine*, **2021**, 82, 100966	16.7	7
37	Big data driven COVID-19 pandemic crisis management: potential approach for global health. *Archives of Medical Science*, **2021**, 17, 829-837	2.9	4
36	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. *Frontiers in Microbiology*, **2021**, 12, 675419	5.7	13
35	Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?. *Archives of Medical Science*, **2021**, 17, 827-828	2.9	1
34	NMNI editorial report, 2020. *New Microbes and New Infections*, **2021**, 41, 100859	4.1	
33	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.		
32	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
31	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. *Drug Metabolism Reviews*, **2021**, 53, 508-541	7	
30	Big Data Research in Fighting COVID-19: Contributions and Techniques. *Big Data and Cognitive Computing*, **2021**, 5, 30	3.5	2
29	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. *Reviews in Medical Virology*, **2021**, e2276	11.7	2
28	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. *The Lancet Regional Health Americas*, **2021**, 2, 100062		9
27	Keeping Meta-Analyses Hygienic During the COVID-19 Pandemic. *Frontiers in Public Health*, **2021**, 9, 722458		0
26	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 166264	6.9	0
25	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. *Molecules*, **2021**, 26,	4.8	12
24	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. *Internal and Emergency Medicine*, **2020**, 15, 1501-1506	3.7	18

23	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. *New Microbes and New Infections*, **2020**, 38, 100770	4.1	10
22	Natural history of COVID-19 and therapeutic options. *Expert Review of Clinical Immunology*, **2020**, 16, 1159-1184	5.1	41
21	Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis.		4
20	Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry. **2020**,		6
19	Science and pseudoscience during the COVID-19 pandemic. *Turk Pediatri Arsivi*, **2020**, 55, 335-336	0.7	1
18	Application of Big Data Technology for COVID-19 Prevention and Control in China: Lessons and Recommendations. *Journal of Medical Internet Research*, **2020**, 22, e21980	7.6	39
17	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. *Annals of the Academy of Medicine, Singapore*, **2020**, 49,	2.8	7
16	Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. *Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapia*, **2020**, 22, 164-174	1.3	
15	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. *Profilakticheskaya Meditsina*, **2020**, 123, 74	0.5	
14	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. *Annals of the Academy of Medicine, Singapore*, **2020**,	2.8	1
13	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. *American Journal of Cardiovascular Disease*, **2021**, 11, 93-107	0.9	9
12	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. *Future Virology*, **2021**,	2.4	2
11	Analysis of Selected Twitter Headers During the Pandemic Using Big Data Method. *Accounting, Finance, Sustainability, Governance & Fraud*, **2022**, 257-273	0.1	1
10	Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.. *International Journal of Infectious Diseases*, **2021**,	10.5	0
9	Big Data COVID-19 Systematic Literature Review: Pandemic Crisis. *Electronics (Switzerland)*, **2021**, 10, 3125	2.6	7
8	Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19.. *American Journal of Therapeutics*, **2022**, 29, e237-e244	1	0
7	-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.. *Medicina (Lithuania)*, **2022**, 58,	3.1	1
6	Drug safety of frequently used drugs and substances for self-medication in COVID-19.. *Therapeutic Advances in Drug Safety*, **2022**, 13, 20420986221094141	3.5	0

5	Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. **2022**, 5,	0
4	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. **2022**, 44,	0
3	Computational approaches for drug discovery against COVID-19. **2023**, 321-337	0
2	Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525	0
1	Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients.	0